TAIHO PHARMA

Exploring hidden
possibilities for
people awaiting
new medicines

We mourn the loss of those who have died from COVID-19, extend our sympathies to their loved ones, wish COVID-19 survivors rapid and permanent recoveries, and express our gratitude to medical professionals and others who support the ill.

About Taiho

Becoming a truly global specialty pharma that meets the expectations of patients worldwide.

Our Business

Taiho Pharmaceutical creates innovative, highly valuable new drugs to support patients and the advancement of medicine, seeking to contribute to smiles and health for people all around the world.

News Releases

April 02, 2021

FDA Grants Breakthrough Therapy Designation for Taiho Pharmaceutical Originated Futibatinib for Treatment of Advanced Cholangiocarcinoma（PDF：433.6 KB）
March 23, 2021

Taiho Pharmaceutical Submits New Drug Application for NK₁ Receptor Antagonist Fosnetupitant for Prevention of Gastrointestinal Symptoms (Nausea and Vomiting) Associated with Cancer Chemotherapy
March 09, 2021

Taiho Pharmaceutical Announces Personnel Changes（PDF：82.6 KB）
February 22, 2021

Taiho Pharmaceutical's TAS-116, an Oral HSP90 Inhibitor, Shows Significantly Prolonged
Progression-Free Survival in Patients with GIST in Phase-III Clinical Trial
February 09, 2021

Office Divisions of Five Otsuka Group Companies to Switch to Green Power（PDF：102.5 KB）

Information

February 12, 2021

Otsuka Holdings announces FY2020 financial results
July 12, 2018

Announcement of Support from Otsuka Holdings and Its Group Companies in the Aftermath of Severe Storms in Japan（PDF：165.9 KB）